Jeisys Medical Inc. (287410.KQ)
KRW 12900.0
(0.16%)
KRW 12900.0
(0.16%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 32.67 Billion | 25.25 Billion | 20.3 Billion | 16.12 Billion | 53.08 Million |
| Net Income | 25.1 Billion | 27.01 Billion | 13.49 Billion | 7.54 Billion | 39.6 Million |
| Depreciation & Amortization | 4.26 Billion | 3.04 Billion | 2.47 Billion | 2.32 Billion | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 1.58 Billion | 2.02 Billion | 1.63 Billion | 265.2 Million | - |
| Change in working capital | -2.37 Billion | -13.22 Billion | -5.47 Billion | 1.14 Billion | 57.35 Thousand |
| Other non-cash items | 100.57 Million | 358.12 Million | 10.82 Billion | 966.3 Million | 13.42 Million |
| Investing Cash Flow | -17.65 Billion | -21.09 Billion | 5.68 Billion | -3.39 Billion | -105.41 Million |
| Investments in PPE | -15.01 Billion | -13.51 Billion | -2.78 Billion | -2.97 Billion | - |
| Acquisitions | - | - | 962.47 Million | - | - |
| Investment purchases | -2.14 Billion | -9.82 Billion | -318.75 Million | -688.7 Million | -7.1 Billion |
| Sales/Maturities of investments | 207.23 Million | 2.3 Billion | 7.91 Billion | 267.6 Million | 7 Billion |
| Other Investing Activities | -728.24 Million | -97.74 Million | -100.44 Million | -25.9 Million | - |
| Financing Cash Flow | -5.09 Billion | 2.01 Billion | -9.3 Billion | -684.97 Million | - |
| Debt repayment | -9.05 Billion | -3.2 Billion | -579.91 Million | -152.75 Million | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -10 Billion | - | -263.7 Million | - | - |
| Common Stock Issuance | 7.77 Billion | - | - | - | - |
| Other Financing Activities | -10.37 Billion | -318.07 Million | -7.54 Billion | 34 Million | - |
| Accounts receivables | -6.39 Billion | -4.02 Billion | -3.52 Billion | 638.85 Million | - |
| Accounts payables | - | - | - | - | - |
| Inventory | -2.7 Billion | -10.01 Billion | -5.58 Billion | 703.38 Million | - |
| Other working capital | 5.51 Billion | 854.62 Million | 2.54 Billion | -370.11 Million | 57.35 Thousand |
| Cash at beginning of period | 39.58 Billion | 34.29 Billion | 17.59 Billion | 6.08 Billion | 1.16 Billion |
| Cash at end of period | 48.83 Billion | 39.58 Billion | 34.29 Billion | 17.59 Billion | 1.11 Billion |
| Capital Expenditure | -15.01 Billion | -13.51 Billion | -2.78 Billion | -2.97 Billion | - |
| Effect of forex changes on cash | -678.4 Million | -877.85 Million | 27.84 Million | -533.76 Million | - |
| Net cash flow / Change in cash | 9.24 Billion | 5.29 Billion | 16.7 Billion | 11.5 Billion | -52.32 Million |
| Free Cash Flow | 17.66 Billion | 11.73 Billion | 17.51 Billion | 13.14 Billion | 53.08 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 9.12 Billion | 7.02 Billion | 25.1 Billion | 4.12 Billion | 8.05 Billion | 6.24 Billion |
| Depreciation & Amortization | 1.14 Billion | 1.16 Billion | 4.26 Billion | 1.12 Billion | 1.09 Billion | 1.04 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 223.79 Million | 333.97 Million | 1.58 Billion | 398.99 Million | 368.26 Million | 437.98 Million |
| Change in working capital | -7.98 Billion | -1.06 Billion | -2.37 Billion | -1.47 Billion | -2.78 Billion | 987.01 Million |
| Other non-cash items | 3.39 Billion | 62.25 Million | 100.57 Million | -67.34 Million | 34.08 Million | 52.55 Million |
| Investing Cash Flow | -55.49 Billion | -761.26 Million | -17.65 Billion | -13.49 Billion | -1.3 Billion | -1.6 Billion |
| Investments in PPE | -6.34 Billion | -388.98 Million | -15.01 Billion | -12.81 Billion | -428.26 Million | -1.16 Billion |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -309.29 Million | -2.14 Billion | -677.38 Million | -850.27 Million | -306.93 Million |
| Sales/Maturities of investments | - | - | 207.23 Million | - | - | - |
| Other Investing Activities | -49.15 Billion | -64.46 Million | -728.24 Million | -16.27 Million | -231.7 Million | -138.05 Million |
| Financing Cash Flow | 5.69 Billion | 39.63 Billion | -5.09 Billion | 11.43 Billion | -15.8 Billion | -4.83 Billion |
| Debt repayment | -607.29 Million | -39.87 Billion | -9.05 Billion | -11.36 Billion | -2.04 Billion | -166.25 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -10 Billion | -230.00 | -5.53 Billion | -4.46 Billion |
| Common Stock Issuance | - | 154.56 Million | 7.77 Billion | -230.00 | 169.81 Million | 325.96 Million |
| Other Financing Activities | 6.3 Billion | 10.00 | -10.37 Billion | 448.14 Million | -8 Billion | -112.37 Million |
| Accounts receivables | 2 Billion | -3.09 Billion | -6.39 Billion | -3.32 Billion | -2.58 Billion | -3.96 Billion |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -3.14 Billion | -1.65 Billion | -2.7 Billion | -1.32 Billion | -81.42 Million | -1.35 Billion |
| Other working capital | -6.84 Billion | 4.2 Billion | 5.51 Billion | 2.79 Billion | -283.99 Million | 5.55 Billion |
| Cash at beginning of period | 96.58 Billion | 48.83 Billion | 39.58 Billion | 41.43 Billion | 52.59 Billion | 52.01 Billion |
| Cash at end of period | 52.93 Billion | 96.58 Billion | 48.83 Billion | 48.83 Billion | 41.43 Billion | 52.59 Billion |
| Capital Expenditure | -6.34 Billion | -388.98 Million | -15.01 Billion | -12.81 Billion | -428.26 Million | -1.16 Billion |
| Effect of forex changes on cash | 257.24 Million | -491.94 Million | -678.4 Million | 350.87 Million | 83.68 Million | -2.09 Billion |
| Net cash flow / Change in cash | -43.64 Billion | 47.75 Billion | 9.24 Billion | 7.39 Billion | -11.15 Billion | 576.03 Million |
| Free Cash Flow | -443.66 Million | 8.97 Billion | 17.66 Billion | -3.71 Billion | 5.43 Billion | 7.95 Billion |
NSPR
PPS
ADGCF
RXRX
603606
MANAPPURAM